Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires Shares of 34,752 West Pharmaceutical Services, Inc. $WST

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 34,752 shares of the medical instruments supplier’s stock, valued at approximately $9,562,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of West Pharmaceutical Services by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,704,948 shares of the medical instruments supplier’s stock valued at $2,545,899,000 after buying an additional 388,144 shares during the last quarter. State Street Corp boosted its stake in shares of West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after buying an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of West Pharmaceutical Services by 22.2% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock valued at $726,895,000 after buying an additional 503,601 shares during the last quarter. Durable Capital Partners LP boosted its stake in shares of West Pharmaceutical Services by 12.7% during the 3rd quarter. Durable Capital Partners LP now owns 1,172,583 shares of the medical instruments supplier’s stock valued at $307,604,000 after buying an additional 131,935 shares during the last quarter. Finally, TD Asset Management Inc boosted its stake in shares of West Pharmaceutical Services by 26.1% during the 3rd quarter. TD Asset Management Inc now owns 606,332 shares of the medical instruments supplier’s stock valued at $159,059,000 after buying an additional 125,398 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on WST. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Morgan Stanley set a $315.00 price objective on West Pharmaceutical Services in a research note on Monday, April 27th. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Jefferies Financial Group reiterated a “buy” rating and issued a $295.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $322.89.

West Pharmaceutical Services Stock Performance

WST stock opened at $304.47 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The stock has a market capitalization of $21.51 billion, a price-to-earnings ratio of 40.70, a PEG ratio of 2.55 and a beta of 1.17. West Pharmaceutical Services, Inc. has a 1 year low of $203.74 and a 1 year high of $330.88. The stock’s fifty day moving average is $271.08 and its two-hundred day moving average is $265.56.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period last year, the business posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, research analysts predict that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

West Pharmaceutical Services declared that its Board of Directors has approved a share repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is currently owned by company insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.